NCT04396808Active, not recruiting
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 805 (actual)
- First submitted
- 15 May 2020
- Start date
- 5 Nov 2020
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT04396808
What you commit to
- Study type: Interventional
- Participants enrolled: 805
- From 5 Nov 2020 to the primary completion date, 31 Mar 2028
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior prostate cancer treatment, including prostatectomy, radiation therapy, or hormone therapy.
- Prior prostate gene expression classier testing
Other illness
- Clinical (on digital rectal exam) or radiographic evidence (if MRI performed) of T3 disease
- Nodal or metastatic prostate cancer (if staging imaging performed)
Who the study is looking for
- Prostate cancer patients who have undergone diagnostic prostate biopsy in the past 9 months.
- Prostate biopsy tumor tissue (FFPR block) available for processing
- Age 18 years or older
- PSA \<20 ng/ml
- Grade Group (GG) 1 cancer with \> 2 biopsy cores involved with cancer OR GG2 cancer
- Ability to understand and the willingness to sign a written informed consent. A subject's legally acceptable representative may sign the consent form.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Rogel Cancer Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| University of North Carolina Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
| Sherwood Medical Center Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
| Henry Ford Health System Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
| Spectrum Health Medical Group Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Western Michigan Urological Associates Coordinator of this site? Confirm its status | Holland | United States | Unknown status |
| University of Pennsylvania Perelman School of Medicine Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Montefiore Medical Center Coordinator of this site? Confirm its status | The Bronx | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.